The FDA has approved intravenous immunoglobulin (IVIG) [human]-kthm 10% liquid (Qivigy; Kedrion Biopharma) for the treatment of adults with primary humoral immunodeficiency (PI), according to a news release from Kedrion Biopharma. With a new formulation of IVIG now available, patients with PI and other immunodeficiencies have more options than ever to address their unmet needs and reduce the impact of their condition on their daily lives.1What is Primary Immunodeficiency? The conditions primary feature an inability for the body to effectively fight infections. Kedrion Biopharma receives FDA approval for Qivigy (immune globulin 10% IV) for treatment of primary humoral immunodeficiency in adults and confirms its plan to increase investments in the U.S. throughout its global operations. Clinical assessment of pharmacokinetics, efficacy, and safety of 10% IVIg in PID patients (CARES10).